Abstract
Tislelizumab combined with chemotherapy was approved for first-line treatment of advanced squamous cell lung carcinoma and non-squamous non-small cell lung carcinoma in China. This study aimed to evaluate the efficacy of neoadjuvant Tislelizumab plus chemotherapy in resectable stage IIIA-B NSCLC in a real-world setting.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
